Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.64 |
| ▸ | CNR2 | P34972 | 3/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163060 | 0.92 | LMNA (0.57) | ESR1CNR2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL162777 | 0.86 | TSHR (0.53) | ESR1CNR2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL163865 | 0.85 | CA12 (0.57) | ESR1CYP1A2CYP2D6MAPK1CYP2C19 | |
| SCHEMBL29809757 | 0.83 | ESR1 (0.59) | ESR1CNR2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL29036652 | 0.81 | L3MBTL1 (0.44) | ESR1CNR2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL29809830 | 0.81 | ESR1 (0.57) | ESR1CNR2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL15910310 | 0.80 | TSHR (0.58) | ESR1TSHRLMNACYP1A2CYP2D6 | |
| SCHEMBL11527051 | 0.80 | HRH3 (0.64) | ESR1TSHRLMNACYP1A2CYP2D6 | |
| SCHEMBL164016 | 0.79 | ALDH1A1 (0.51) | TSHRSMN1; SMN2TDP1L3MBTL1SERPINE1 | |
| Butyl Gallate SCHEMBL35913 | 0.79 | ESR1 (1.00) | ESR1CNR2AKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | ESR1 4725/4885CNR2 3729/4885AKR1C4 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.